Canagliflozin (hemihydrate): High-Purity SGLT2 Inhibitor for Glucose Homeostasis Research

Executive Summary: Canagliflozin (hemihydrate) is a selective sodium-glucose co-transporter 2 (SGLT2) inhibitor supplied at ≥98% purity by APExBIO, optimized for metabolic and diabetes research (APExBIO product page). It effectively blocks renal glucose reabsorption, promoting glucose excretion and lowering blood glucose levels in experimental models (Canagliflozin: High-Purity SGLT2 Inhibitor). Recent peer-reviewed data demonstrate that canagliflozin does not inhibit the mTOR pathway, clarifying its mechanistic specificity (Breen et al., 2025). The compound is water-insoluble but highly soluble in ethanol and DMSO, supporting diverse assay designs. Recommended storage at -20°C and prompt use of solutions maintains its integrity for reproducible results.

Biological Rationale

Diabetes mellitus is characterized by dysregulated glucose homeostasis, often due to impaired insulin signaling and excessive renal glucose reabsorption. SGLT2, predominantly expressed in the proximal renal tubules, mediates the majority of filtered glucose reabsorption. Inhibition of SGLT2 disrupts this process, offering a non-insulin-dependent approach to reducing hyperglycemia. Canagliflozin (hemihydrate) is a small molecule inhibitor specifically targeting SGLT2, enabling researchers to dissect the contribution of renal glucose handling in metabolic disease models (Canagliflozin Hemihydrate in SGLT2 Inhibition). Unlike agents that modulate insulin secretion or sensitivity, SGLT2 inhibitors act directly at the renal level, bypassing pancreatic or hepatic confounders and providing a focused tool for glucose metabolism research.

Mechanism of Action of Canagliflozin (hemihydrate)

Canagliflozin (hemihydrate) binds selectively to the SGLT2 transporter on the luminal surface of renal proximal tubule cells. This interaction prevents sodium-coupled glucose reabsorption, increasing urinary glucose excretion. The compound does not significantly inhibit SGLT1 at pharmacologically relevant concentrations, ensuring specificity for glucose homeostasis pathways (see Canagliflozin (Hemihydrate): Mechanistic Precision). Its action is independent of insulin and does not directly modulate mTOR or other nutrient-sensing pathways, as confirmed in recent yeast-based mTOR inhibitor screens (Breen et al., 2025).

Evidence & Benchmarks

• Canagliflozin (hemihydrate) inhibits SGLT2-mediated glucose reabsorption in renal cell models, reducing glucose uptake rates by >90% at μM concentrations (see product data).
• High-purity batches (≥98%) supplied by APExBIO are validated by HPLC and NMR, ensuring reproducibility in metabolic disorder research (APExBIO).
• Canagliflozin exhibits no off-target mTOR pathway inhibition in drug-sensitized yeast models at concentrations up to 100 μM (Breen et al., 2025, DOI).
• Compound is insoluble in water but soluble in ethanol (≥40.2 mg/mL) and DMSO (≥83.4 mg/mL), facilitating a range of in vitro assays (APExBIO).
• Optimal storage at -20°C and prompt use of solutions maintain compound integrity and experimental reliability (APExBIO).

Applications, Limits & Misconceptions

Canagliflozin (hemihydrate) is ideal for:

• Modeling glucose homeostasis and renal glucose reabsorption in cell-based and animal studies.
• Screening for SGLT2 inhibitor efficacy in diabetes mellitus research, enabling pathway-specific investigations.
• Dissecting the impact of SGLT2 inhibition on metabolic disorder models without confounding mTOR or insulin signaling effects.

This article updates prior overviews such as Redefining Glucose Homeostasis Research by clarifying compound specificity and mTOR exclusion, and extends the experimental best practices outlined in Optimizing Glucose Metabolism Research with Canagliflozin by introducing recent validation data.

Common Pitfalls or Misconceptions

• Not an mTOR inhibitor: Canagliflozin (hemihydrate) does not inhibit mTOR signaling in yeast or mammalian models at research-relevant concentrations (Breen et al., 2025).
• Not suitable for long-term solution storage: Prepared solutions degrade over time; use promptly after preparation for optimal results (APExBIO).
• Not water-soluble: Compound is insoluble in water—use ethanol or DMSO for dissolution (APExBIO).
• Not for diagnostic or therapeutic use: For research use only; not approved for in vivo human administration.
• Does not affect SGLT1 at standard concentrations: Selectivity for SGLT2 minimizes off-target effects in typical assay ranges.

Workflow Integration & Parameters

For optimal laboratory use, dissolve Canagliflozin (hemihydrate) in DMSO or ethanol to achieve desired concentrations—≥40.2 mg/mL in ethanol or ≥83.4 mg/mL in DMSO (APExBIO). Store solid compound at -20°C. Solutions should be prepared fresh prior to use. For in vitro assays, typical working concentrations range from 0.1–50 μM depending on the cell model and endpoint. Always include appropriate controls for solvent and SGLT2 specificity. For detailed protocol guidance and troubleshooting, see Canagliflozin (hemihydrate): High-Purity SGLT2 Inhibitor, which this article extends by offering updated mTOR pathway specificity data.

Conclusion & Outlook

Canagliflozin (hemihydrate), as supplied by APExBIO (SKU C6434), is a rigorously validated SGLT2 inhibitor for targeted glucose metabolism and diabetes research. Its documented specificity, high purity, and optimized physicochemical characteristics support advanced study designs requiring precise modulation of renal glucose reabsorption. Recent exclusion of mTOR pathway effects enhances its value in differentiating metabolic from growth signaling pathways. For further information, ordering, and technical data, refer to the Canagliflozin (hemihydrate) product page.